EFFECT OF NON IONIC SURFACTANT ON THE SOLUBILITY AND DISSOLUTION OF SIMVASTATIN
Kumar Sandeep¹,²*, Purohit Suresh¹,³ and Gupta G D¹,²
¹Jodhpur National University, Jodhpur, India
²ASBASJS Memorial College of Pharmacy, Bela Ropar, Punjab, India
³P.D.M. College of Pharmacy, Bahadurgarh, India

Article Received on: 17/01/2011 Revised on: 16/02/2011 Approved for publication: 02/03/2011

* Sandeep Kumar, Jodhpur National University, Jodhpur, India E-mail: sandeep_pharm70@yahoo.com

ABSTRACT
Various investigators have been facing the problems in improving solubility, dissolution and bioavailability of poorly water soluble drugs. Solid dispersion is a unique approach to improve the solubility of poorly water soluble drugs. In the present study an attempt has been made to improve the solubility and dissolution of poorly soluble drug Simvastatin (SIM) using Poloxamer 188 (PXM) as carrier. The kneading technique was used to prepare solid dispersions in different ratios. In conclusion, solubility and dissolution enhancement of SIM was improved by preparing its solid dispersion with PXM.

KEYWORDS: Simvastatin, Poloxamer188, Solid dispersion, Kneading.

INTRODUCTION
For a drug to enter the systemic circulation to exert a therapeutic effect, it must possess some aqueous solubility. The improvement of solubility or dissolution has been a challenging task for the investigators for the years. Recent technologies innovation of combinatorial chemistry and high throughput screening can effectively discover the seeds of new drugs, which present good pharmacological activities. However, some of these new drugs discovered by those technologies suffer from poor aqueous solubility. Many methods have been reported for solubility and dissolution enhancement of poorly soluble drugs such as micronization, complexation, solid dispersions etc. Solid dispersion of many poorly water soluble drugs by incorporating them into a water soluble polymer matrix has been considered as an effective method for improving drug dissolution rate and their saturation solubility in the gastrointestinal fluids. Poloxamers are polyoxyethylene-polypropylene block copolymer nonionic surfactants that have been widely used as wetting and solubilizing agents and surface adsorption excipients. Poloxamer 188 (PXM) is empirically selected to prepare solid dispersions because of its low melting point (about 56–57°C), surfactant properties, and oral safety.

Simvastatin (SIM) is a cholesterol lowering agent, which is a white, non-hygroscopic, crystalline powder having poor aqueous solubility and bioavailability. SIM is a potential inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. It catalyzes the conversion of HMG-CoA to mevalonate; this conversion is an early and rate-limiting step in the biosynthesis of cholesterol. The drug is poorly absorbed from the gastrointestinal (GI) tract; therefore, it is important to enhance the aqueous solubility, dissolution rate, and bioavailability from its oral solid dosage forms.

In current study, an attempt was made to increase solubility and dissolution of Simvastatin by solid dispersion technique using hydrophilic carrier such as poloxamer 188.

MATERIALS AND METHODS
Simvastatin and poloxamer 188 were generously gifted from Ind-Swift laboratories Ltd., Punjab and Signet chemical corporation Ltd., Mumbai respectively. All other chemicals were of analytical grade and were used as such.

Preparation of solid dispersions
Physical mixtures were prepared by mixing accurate weight of SIM with PXM in drug: polymer ratio of 1:2, 1:5, and 1:8 using glass mortar and pestle. The physical mixtures were kneaded for 30 minutes using a small volume of ethanol-water (1:1) solution to give a thick paste. The kneaded paste was packed in amber colored glass vials and stored at room temperature.
paste, the wet mass was dried at 45°C, pulverized, passed through 30 mesh sieve size, stored in a desiccator and then passed through 60 mesh sieve size.

**Percent practical yield**

Percent practical yield was determined by following formula

\[ \text{Practical yield} \% = \frac{\text{practical mass (solid dispersion)/theoretical mass (drug+carrier)}}{100} \]

**Drug content**

Solid dispersions equivalent to 10 mg of SIM were weighed accurately and dissolved in suitable quantity of methanol. The drug content was determined at 240 nm by UV spectrophotometer.

**Phase solubility studies**

Solubility measurements were performed in triplicate using the method reported by Higuchi and Connors\(^9\). An excess amount of SIM was added to 10 ml of phosphate buffer (pH 6.8) in test tubes containing increasing concentration of PXM (i.e., 0.1 %, 0.25 %, 0.5%, 0.75%, and 1% w/v) and sealed with stoppers. The test tubes were vortexed for 5 minutes and then sonicated for 30 minutes. They were kept on constant temperature shaking bath maintained at 37±0.5°C until reaching equilibrium (48h). Subsequently, the suspensions were filtered through 0.45µm membrane filter, and the filtered solutions were properly diluted. Drug concentration was determined spectrophotometrically at 240 nm.

**Determination of solubility**

SIM and solid dispersions equivalent to 10 mg of SIM were added to 20 ml phosphate buffer (pH 6.8) in screw-capped test tubes, vortexed for 2 minutes and shaken at 37±0.5°C temperature for 24 h. Resultant samples containing undissolved solid dispersions suspended in a test medium were centrifuged at 10,000 rpm for 5 min and the clear supernatants obtained were filtered, suitably diluted and analyzed spectrophotometrically at 240 nm.

**Dissolution studies**

Solid dispersions equivalent to 10 mg of SIM were placed in the dissolution vessels containing 900 ml of phosphate buffer (pH 6.8) maintained at 37±0.5°C temperature and stirred at 100 rpm. Samples were collected periodically and replaced with fresh dissolution medium. Concentration of SIM was determined spectrophotometrically at 240 nm. Dissolution efficiency (DE) was calculated from the area under dissolution curves at given time and expressed as a percent of the area of the rectangle described by 100 % dissolution in the same time\(^10\).

**RESULTS AND DISCUSSION**

**Drug content**

The drug content of the prepared solid dispersions was found to be in the range of 95.6-100.30 % indicating the application of present method for the preparation of solid dispersions with high content uniformity.

**Phase solubility studies**

The % yield was calculated to know about % yield or efficiency of any method, which helps in selection of appropriate method of production. Initially there was observed increase in % yield as drug: carrier ratio was increased from 1:2 to 1:5 but thereafter there was observed decrease in % yield, which is attributed to difficulty of sieving when higher polymer ratio was used (fig.1).

**Solubility studies**

Solubility of SIM in phosphate buffer (pH6.8) was found to be 18.5±1.02 µg/ml while improvement in solubility was observed with all solid dispersions. Increase in weight fraction of surface active carrier results in increase in solubility of all solid dispersions. Maximum solubility enhancement was found in 1:8 drug polymer ratio. Solubility enhancement can be explained by its wetting and solubilizing nature.

**In vitro dissolution studies**

The enhanced dissolution rate with poloxamer 188 may be attributed to its surfactant activity which facilitates wetting and subsequent solubilization of drug. Poloxamer 188 has HLB value of 29 and has great tendency to solubilize the drugs.

**REFERENCES**


Table 1: Solubility of Simvastatin in phosphate buffer solution (pH6.8)

<table>
<thead>
<tr>
<th>S. No</th>
<th>Drug: carrier ratio</th>
<th>Solubility(µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Simvastatin 1:2</td>
<td>18.5±1.02</td>
</tr>
<tr>
<td>2</td>
<td>1:5</td>
<td>24.2±1.50</td>
</tr>
<tr>
<td>3</td>
<td>1:8</td>
<td>33.6±0.78</td>
</tr>
<tr>
<td>4</td>
<td>1:9</td>
<td>42.4±0.83</td>
</tr>
</tbody>
</table>

All results were calculated as mean±SD, n=3

Table 2: Dissolution efficiency of the prepared solid dispersions

<table>
<thead>
<tr>
<th>S. No</th>
<th>Drug: carrier ratio</th>
<th>% DE 60</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Simvastatin 1:2</td>
<td>21.25±0.92</td>
</tr>
<tr>
<td>2</td>
<td>1:5</td>
<td>32.44±0.41</td>
</tr>
<tr>
<td>3</td>
<td>1:8</td>
<td>40.75±0.74</td>
</tr>
<tr>
<td>4</td>
<td>1:9</td>
<td>42.64±0.65</td>
</tr>
</tbody>
</table>

All results were calculated as mean±SD, n=3

Source of support: Nil, Conflict of interest: None Declared